Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RadiCal
NCT04071223Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2020
- Primary completion
- Jul 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of radium-223 dichloride in renal cell carcinoma (RCC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Symptomatic skeletal event-free survival up to 5 years. Started Jul 2020; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04071223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04071223.